OR WAIT null SECS
August 02, 2019
The evolution of CDMOs has led to increased investment in new technologies, capabilities, and expertise.
July 02, 2019
Nanotechnology is enabling enhanced bioavailability, improved stability, and targeted delivery of challenging APIs.
June 19, 2019
New CDMO facility supports early-stage API manufacturing and scale up.
February 19, 2019
In a deal worth $530 million, the companies will develop and commercialize an anti-epileptic drug candidate in Europe.
December 02, 2018
Antibody-based drugs offer new mechanisms of action and greater specificity.
November 02, 2018
Demand for highly potent APIs continues to rise.
October 02, 2018
Integration of new modeling and analytical tools with flow chemistry are notable trends.
September 18, 2018
The $425-million acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.
September 04, 2018
As it investigates the root cause of an impurity discovered in valsartan, FDA extends its studies to APIs with similar synthesis processes.
September 02, 2018
Existing software tools cannot take into account the complexity of disease.